These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19075639)

  • 41. Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films.
    Izumi M; Morita S; Nishian Y; Miyamoto T; Kasumoto H; Oue M; Hori K; Kitamura R; Yamamoto S; Nakanishi T
    Ren Fail; 2008; 30(10):952-8. PubMed ID: 19016145
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
    Suki WN;
    J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of switch from sevelamer hydrochloride to lanthanum carbonate on serum K and bone metabolic turnover.
    Ota S; Hirose M; Izumiya Y; Ishida Y
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():49-53. PubMed ID: 23586513
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Bommer J; Locatelli F; Satayathum S; Keen ML; Goodkin DA; Saito A; Akiba T; Port FK; Young EW
    Am J Kidney Dis; 2004 Oct; 44(4):661-71. PubMed ID: 15384017
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
    Sun PP; Perianayagam MC; Jaber BL
    J Ren Nutr; 2009 Sep; 19(5):432-8. PubMed ID: 19464926
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of switching from sevelamer hydrochloride to bixalomer on laboratory parameters in hemodialysis patients.
    Furukawa K; Ikawa T; Yokoi S; Yokouchi S; Kato K; Ueno M; Takahashi J
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():2-7. PubMed ID: 24975888
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study.
    Lai B; Cervelli MJ
    Nephrology (Carlton); 2012 May; 17(4):402-6. PubMed ID: 22329674
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
    Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.
    St Peter WL; Liu J; Weinhandl E; Fan Q
    Am J Kidney Dis; 2008 Mar; 51(3):445-54. PubMed ID: 18295060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
    Mohammed I; Hutchison AJ
    J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The details bedevil DCOR.
    Silver J
    Kidney Int; 2007 Nov; 72(9):1041-3. PubMed ID: 17943149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.
    Koiwa F; Kazama JJ; Tokumoto A; Onoda N; Kato H; Okada T; Nii-Kono T; Fukagawa M; Shigematsu T;
    Ther Apher Dial; 2005 Aug; 9(4):336-9. PubMed ID: 16076378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of sevelamer carbonate in increasing serum bicarbonate in hyperphosphatemic predialysis patients who have metabolic acidosis.
    Bezzaoucha S; Pichette V; Lafrance JP; Bell R; Laurin LP; Vallée M
    Int J Clin Pharmacol Ther; 2013 Dec; 51(12):989-90. PubMed ID: 24075095
    [No Abstract]   [Full Text] [Related]  

  • 56. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
    Bleyer AJ; Burke SK; Dillon M; Garrett B; Kant KS; Lynch D; Rahman SN; Schoenfeld P; Teitelbaum I; Zeig S; Slatopolsky E
    Am J Kidney Dis; 1999 Apr; 33(4):694-701. PubMed ID: 10196011
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
    Nolan CR; Qunibi WY
    Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical experiences of bixalomer usage at our hospital.
    Shima H; Makino R; Hata K; Ban A; Funao K; Sugita S; Furumitsu Y; Inoue K; Yoshimoto M; Okamura M
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():13-8. PubMed ID: 24975890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
    Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
    Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.